Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. - Wikidata - thesis-toulmin - TriplyDB

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

http://www.wikidata.org/entity/Q33638930

about

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer Tuberculosis Biomarkers: From Diagnosis to Protection Diagnostic 'omics' for active tuberculosis Transformative tools for tackling tuberculosis Advances in Development of New Treatment for Leishmaniasis Manipulating the in vivo immune response by targeted gene knockdown Assessment of treatment response in tuberculosis Deploying aptameric sensing technology for rapid pandemic monitoring.What was old is new again: using the host response to diagnose infectious disease.A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals.Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis Aptamer-Based Screens of Human Body Fluids for Biomarkers.Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.Selection of Nucleic Acid Aptamers Specific for Mycobacterium tuberculosis.Identification of Host Proteins Predictive of Early Stage Mycobacterium tuberculosis Infection.Proteomics and integrative omic approaches for understanding host-pathogen interactions and infectious diseases.Therapeutic Effect of Recombinant Mutated Interleukin 11 in the Mouse Model of Tuberculosis.Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells.Molecular Elucidation of Disease Biomarkers at the Interface of Chemistry and Biology.

P2860

Q26738703-5915A08F-A3EF-4C36-83F2-78F1BAC71508 Q26741141-0E0FDF5A-8046-49EE-8087-B35B327347C9 Q26752536-D971E5C7-3CA6-45DD-AF00-DDCED3D1BE5F Q26784084-B81DCBE8-D337-44F6-A954-3BA06B706FBF Q28082097-F027C09A-5BFA-43D7-91E9-F568CC06B40A Q28083494-7ED74537-BAFF-46B3-88F1-80B99A415F02 Q28384421-F7F6BFF7-9AE7-4353-8C95-938879C72FB0 Q30252091-092D48DB-1040-46B2-8A9F-B827B25C709E Q30376327-DF53DA71-B0FA-4BB2-AEA1-3A61360913E0 Q33626683-0736F04F-DB1F-4299-8F59-E543B5420E39 Q35309726-4BAA083A-508A-46F0-9977-E27BB2C4E3D5 Q36106333-B55627F0-E0D8-4C49-8CD0-D4465C6723C8 Q36205905-60A81BA8-77F7-4591-A306-D3C08E257690 Q37200787-5E4002BA-47E9-4EBD-B577-0495733D3113 Q38221214-226B3BAE-0747-47C5-85BD-AC83CB3130DC Q38295506-EA23FD75-4D81-4F49-9FC8-923D5EDAAF30 Q38849862-A8898C1D-2EE0-4B7A-B66A-74CA460FC12E Q39203410-04135289-22FB-48C5-BDFF-0E4C28EAE2DC Q40670538-B7911AD8-6898-4358-9635-947C6FD1560F Q42285243-A75650F4-AE6C-46C7-A24B-7D8CD05EA145 Q47104871-73B7F195-7DA9-4F51-8663-3478E3A3BACE Q48148269-C7E301B5-AC6C-4FFA-B882-4FFAE3937C3D Q48313209-4DA67595-BBBB-4DB1-B62E-AC6514B8C79F

P2860

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

http://www.wikidata.org/entity/Q33638930

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Aptamer-based proteomic signat ...... nse in pulmonary tuberculosis.

@ast

Aptamer-based proteomic signat ...... nse in pulmonary tuberculosis.

@en

type

label

Aptamer-based proteomic signat ...... nse in pulmonary tuberculosis.

@ast

Aptamer-based proteomic signat ...... nse in pulmonary tuberculosis.

@en

prefLabel

Aptamer-based proteomic signat ...... nse in pulmonary tuberculosis.

@ast

Aptamer-based proteomic signat ...... nse in pulmonary tuberculosis.

@en

P1433

Q33638930-1E8BCBAD-D0AF-4DC4-9B4A-97B58CF8DAAF

P1476

Q33638930-724875A1-0083-483B-9CA2-BD74525E9209

P2093

Q33638930-1835F5F9-67DF-43A8-9628-E73EB21A0EAB

Q33638930-300136BD-14CA-4102-9251-BD5A9690BC20

Q33638930-3887A8C9-8AB2-4471-98EB-33EBA77D5C70

Q33638930-41CBB0C3-87FA-4A26-9552-B60690447C9D

Q33638930-41E517A7-2CB1-41DE-B953-2DD6F41D71EC

Q33638930-6567FFAA-175D-4050-B651-70A733CAB334

Q33638930-6BDB2308-5A4F-43AA-88FD-607EB7221063

Q33638930-7136F7AF-8EBF-4F2B-B54B-07CEA231F3CB

Q33638930-C3FB3AFA-195D-46E7-AF73-7E1A741A5F87

Q33638930-FA492856-1573-4CA0-9649-7FE3812BD306

P2860

Q33638930-059E795D-FF08-49CA-B591-9C72E0BFCC2E

Q33638930-070C61A1-6C73-4025-81D2-71931EA94278

Q33638930-11B1FA23-75D7-4961-A07A-A933D4E0A4FE

Q33638930-19A598A6-30CF-40E4-9DD7-D8B48BA8EB22

Q33638930-1B35C87E-0836-4B28-8A57-78434874575E

Q33638930-1D2508E0-3669-44A1-B95B-9F591016C19B

Q33638930-1E5EDE67-72CA-4694-9228-9FD6763CBBF3

Q33638930-36265252-2354-4036-A2D6-B43E598590F6

Q33638930-363641F8-B463-4949-87B2-1EA736076958

Q33638930-368F62D1-9538-4E66-A228-58906A41DADF

P304

Q33638930-0999B0C1-E9F7-4531-B132-B8CDD0B17E2B

P31

Q33638930-8EFACF41-A077-4CC8-B0DF-6D093CB73D3D

P356

Q33638930-43F01E12-64BB-4791-88AA-BEF87D2C0420

P433

Q33638930-D37C475C-56AF-42A8-9786-D68EDD36E44F

P478

Q33638930-30DE2486-03EF-4345-A3E5-54D62F55224F

P50

Q33638930-847C3E0E-CEB7-4FBA-8391-ED27F3665E0F

P577

Q33638930-7EBCE309-8DDF-484F-9759-50AE7A287E99

P698

Q33638930-3DAB266A-3BDF-4825-8D85-17F16CB60EB3

P921

Q33638930-BE469A43-CB7B-441E-8F88-001E38F6EC0E

P932

Q33638930-8B3046EB-7B8E-4BCC-9D9D-137A86C5D02C

P356

J.TUBE.2014.01.006

P1433

P1476

Aptamer-based proteomic signat ...... nse in pulmonary tuberculosis.

@en

P2093

David G Sterling

http://www.w3.org/2001/XMLSchema#string

Erin Bliven-Sizemore

http://www.w3.org/2001/XMLSchema#string

Grace Muzanyi

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Leah G Jarlsberg

http://www.w3.org/2001/XMLSchema#string

Marc Weiner

http://www.w3.org/2001/XMLSchema#string

Mary A De Groote

http://www.w3.org/2001/XMLSchema#string

Melissa Engle

http://www.w3.org/2001/XMLSchema#string

Nebojsa Janjic

http://www.w3.org/2001/XMLSchema#string

Urs A Ochsner

http://www.w3.org/2001/XMLSchema#string

P2860

APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity

Interleukin-11 and its receptor

Characterization of the mouse PA28 activator complex gene family: complete organizations of the three member genes and a physical map of the approximately 150-kb region containing the alpha- and beta-subunit genes

Aptamer-based multiplexed proteomic technology for biomarker discovery

Regulation, regulatory activities, and function of biglycan.

Matrix metalloproteinases in tuberculosis.

Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum.

Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum.

Expanding the chemistry of DNA for in vitro selection.

From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay

P304

187-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TUBE.2014.01.006

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24629635

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

4028389

http://www.w3.org/2001/XMLSchema#string